Guardian Pharmacy Services, Inc.

NYSE:GRDN

Medical - Distribution

Healthcare
$48.84 +0.39%

+$0.17 today

Market cap
$3.09B
Beta
0.08
P/E (TTM)
52.0
EPS (TTM)
$0.84
52W Low $19.30High $44.00

Volume 0.45M

Average 0.48M

GRDN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Guardian Pharmacy Services, Inc.NYSE: GRDN

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $2.93M fell 34.1% year over year, ahead of the -92.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 57.5% from the prior quarter.

Context

  • Stock-based compensation amounted to 1.0% of revenue in FY2025, down 9.7 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -34.1% holds above the trailing-twelve-month pace of -92.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.93M+57.5% QoQ
Last fiscal yearDec 2025
$13.85M-89.5% YoY
LTMJun 2026
$10.23M-92.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.1%——
1 year-89.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
13.85M USD
Year-over-year change
-89.5%
4-year CAGR
+1.5%

Stock-Based Compensation vs competitors

How GRDN compares with its peers on the latest reported figures

  • GRDN's LTM Jun 2026 stock-based compensation of $10.23M is the 8th largest of the 11 companies compared; the peer median is $27.74M.
  • Its year-over-year change of -92.4% is the 9th highest of 11, against a peer median of -9.5%.
  • Stock-based compensation amounts to 0.7% of revenue for GRDN, versus a peer median of 11.7%.
GRDN Competitors Peer median
Stock-Based Compensation for GRDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TXG10x Genomics, Inc.LTM Jun 2026$98.74M -20.9%-7.3%16.0%
TWSTTwist Bioscience CorporationLTM Sep 2026$69.86M +8.4%+32.1%15.2%
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$50.57M +41.7%+66.4%15.7%
JANXJanux Therapeutics, Inc.LTM Mar 2026$38.79M +1.8%+32.7%179.5%
QDELQuidelOrtho CorporationLTM Mar 2026$34.2M -23.5%-1.8%1.3%
MDPediatrix Medical Group, Inc.LTM Sep 2026$21.28M +37.8%+3.8%1.1%
NUVBNuvation Bio Inc.LTM Jun 2026$19.89M -153.0%+30.1%11.7%
GRDNGuardian Pharmacy Services, Inc.LTM Jun 2026$10.23M -92.4%—0.7%
NHCNational HealthCare CorporationLTM Sep 2026$6.19M +34.5%+19.0%0.4%
MESOMesoblast LimitedLTM Jun 2026$2.89M -87.0%—2.4%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$1.76M -94.6%+47.1%—
Peer median (excluding GRDN) $27.74M-9.5%+30.1%11.7%

Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income28.33M49.66M37.72M(71.03M)49.22M
Depreciation & Amortization16.53M16.56M18.23M19.77M22.34M
Deferred Income Tax00003.07M
Stock-Based Compensation13.03M(3.38M)(6.09M)131.49M13.85M
Change in Working Capital(1.47M)(18.72M)15.6M(29.41M)6.38M
Accounts Receivables(7.71M)(16.79M)(14.3M)(25.49M)(8.55M)
Inventory(240K)(8.12M)4.43M(1.15M)(877K)
Accounts Payables9.78M13.37M6.3M13.23M16.4M
Other Working Capital(3.3M)(7.17M)19.18M(16M)(586K)
Other Non-Cash Items2.08M4.4M5.35M7.14M5.43M
Operating Cash Flow58.5M48.52M70.82M57.96M100.29M
Capital Expenditures(9.28M)(16.77M)(14.56M)(16.37M)(19.58M)
Acquisitions (Net)(4.4M)(2M)(985K)(14.71M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities535K874K2.1M671K(12.68M)
Investing Cash Flow(13.15M)(17.9M)(13.44M)(30.41M)(32.26M)
Debt Repayment(6.1M)(2.8M)(2.89M)(36.48M)(4.98M)
Common Stock Issued000119.78M27.45M
Common Stock Repurchased000(55.18M)(29.04M)
Dividends Paid(17.36M)(30.8M)(38.42M)(35.75M)0
Other Financing Activities(13.34M)(11.42M)(15.92M)(16.02M)(497K)
Financing Cash Flow(36.79M)(45.03M)(57.23M)(23.65M)(7.07M)
Effect of Forex Changes00000
Net Change in Cash8.56M(14.41M)145K3.91M60.96M
Free Cash Flow49.22M31.75M56.26M41.59M80.71M

Guardian Pharmacy Services, Inc.

NYSE:GRDN

Intrinsic Alpha fair value

Locked

Current Price

$48.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.